Back to top
more

BioCardia (BCDA)

(Delayed Data from NSDQ)

$3.72 USD

3.72
6,647,712

-0.65 (-14.78%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $3.20 -0.52 (-13.98%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BCDA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

BioCardia, Inc. [BCDA]

Reports for Purchase

Showing records 21 - 40 ( 57 total )

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 21

12/16/2022

Company Report

Pages: 4

As We Expected, Raises Capital, but It?s Just a drop in the Bucket - We Remain on the Sidelines Neutral Rated

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 22

12/06/2022

Daily Note

Pages: 5

CardiALLO Receives Green Light to Initiate First-in-Human Phase 1/2 Trial in HF

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 23

11/10/2022

Company Report

Pages: 6

3Q22 Results; CardiAMP Makes Headway in the Clinic as BD Prospects Crystallize

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 24

11/10/2022

Company Report

Pages: 6

Reports 3rd Quarter: Burning $3M/QTR with $6.6M Left on the Balance Sheet - Lowering to Neutral

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 25

10/18/2022

Company Report

Pages: 7

New data from the CardiAMP Cell Therapy HF Trial

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 26

10/05/2022

Company Report

Pages: 9

CardiAMP HF Remains on Track, Backed by Positive Roll- In Cohort Efficacy; Completion of Enrollment in 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 27

10/03/2022

Company Report

Pages: 8

CardiAMP HF Delivers Favorable Two-Year Roll-In Cohort Efficacy Results; Completion of Phase 3 Enrollment in 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 28

08/31/2022

Company Report

Pages: 6

BioCardia announces DSMB Review - OK to Continue

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 29

08/31/2022

Daily Note

Pages: 6

CardiAMP-HF Focused on Enrollment Following Positive DSMB Phase 3 Review

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 30

08/11/2022

Company Report

Pages: 8

2Q22 Results; CardiAMP-HF Ramps Up Enrollment; On Track to Complete Enrollment in 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 31

05/18/2022

Company Report

Pages: 6

Reports 1Q22 Results: Closed with $10M in Cash, Anticipates Cash Can Last to 1Q23

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 32

05/12/2022

Company Report

Pages: 7

1Q22 Results; Stage Is Set For Accelerated Enrollment in CardiAMP Trials While Partnership Activities Develop

Provider: H.C. Wainwright & Co., Inc.

Analyst: BRANCHETTI E

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 33

04/19/2022

Company Report

Pages: 6

Equity Sales Agreement Target Raise $10.5M Adjusting for Dilution our PT Falls: $4.0 to $3.0

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 34

03/30/2022

Company Report

Pages: 7

2021 Results; Key Progress Accelerates CardiAMP Towards Approval

Provider: H.C. Wainwright & Co., Inc.

Analyst: BRANCHETTI E

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 35

03/30/2022

Company Report

Pages: 6

Reports Full Year Results ? Heart Failure Trial Continues to Enroll (110 of 260) so far.

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 36

03/03/2022

Company Report

Pages: 7

Heart Failure Trial expands to Canada

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 37

03/01/2022

Daily Note

Pages: 5

CardiAMP-HF Accelerates Enrollment With Expansion to Canada; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 38

02/14/2022

Company Report

Pages: 7

DSMB Say?s Keep Going - Phase 3 HF Trial

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 39

02/14/2022

Daily Note

Pages: 5

CardiAMP-HF Continues As Planned After Positive DSMB Safety and Futility Review; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: BioCardia, Inc.

Industry: Medical - Drugs

Record: 40

02/03/2022

Daily Note

Pages: 5

CardiAMP Accelerates Path to Approval in HF With Breakthrough Device Designation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party